Age-Related Macular Degeneration (AMD)
Clinical Overview and Systemic Prevention
EDUCATIONAL NOTE: Age‑Related Macular Degeneration (AMD) is a chronic disease affecting the central retina (macula). Scientific literature highlights the contribution of oxidative stress, chronic low‑grade inflammation and genetic susceptibility to disease onset and progression. Well‑established modifiable risk factors include cigarette smoking, certain metabolic disorders and cumulative light exposure. In parallel, specific micronutrients (particularly the xanthophylls lutein and zeaxanthin) have been evaluated in AREDS/AREDS2 trials as supportive strategies in patients with intermediate AMD or advanced AMD in one eye, with the aim of reducing progression to late stages. OCT (Optical Coherence Tomography) is currently a key tool for anatomical assessment and follow‑up of the macular region across different disease stages.
Clinical Factor Dynamics: Risk and Protection
Phototoxicity
Cumulative photo‑oxidative exposure over a lifetime.
Lifestyle
Smoking and diets low in leafy green vegetables and antioxidants.
Systemic Inflammation
Chronic inflammatory state (“inflammaging”) and vascular comorbidities.
AREDS2 Formula
Specific supplementation (lutein, zeaxanthin, antioxidant vitamins, zinc and copper) evaluated in AREDS2 for reducing progression to late AMD in selected patients with intermediate disease.
Nutrition
Diets rich in leafy green vegetables, fish and natural sources of lutein/zeaxanthin are associated with a more favorable macular risk profile.
Metabolic Control
Management of blood pressure, lipids and glycemia as part of overall cardiovascular and metabolic care.
Clinical Notes and Warnings
- MONITORING: The non‑neovascular (dry) form of AMD requires regular clinical and OCT surveillance according to specialist advice.
- SYMPTOMS: New onset of metamorphopsia, central scotoma or sudden visual loss warrants urgent ophthalmologic assessment to exclude conversion to neovascular (wet) AMD.
- SUPPLEMENTATION: AREDS2‑type formulations are not curative and are indicated only for specific subgroups (intermediate AMD or advanced AMD in one eye) as defined in clinical trials; their use and potential systemic contraindications should be discussed with the eye specialist and, when appropriate, the general physician.
- THERAPY: Treatment of neovascular (wet) AMD is based on intravitreal anti‑VEGF injections according to guideline protocols; nutritional and lifestyle measures play only a complementary, not substitutive, role.
Bibliographic References
- Age-Related Eye Disease Study 2 (AREDS2) Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration. JAMA, 2013.
- Schmidt-Erfurth U, et al. Guidelines for the management of neovascular age-related macular degeneration. Br J Ophthalmol, 2014.
- Chakravarthy U, et al. Clinical risk factors for age-related macular degeneration: a systematic review. BMC Ophthalmology, 2010.